Daphne Teo logo

Daphne Teo

Asia, Singapore

Description

Daphne Teo is the CEO and founder of NSG BioLabs.

Investor Profile

Daphne Teo has made 1 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series C (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Daphne Teo frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 1
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 1
CLI Ventures
North America, California, United States, Palo Alto
Co-Investments: 1
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Ally Bridge Group
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 1
Deerfield
North America, New York, United States, New York
Co-Investments: 1
Aju IB Investment
Asia, Seoul-t'ukpyolsi, South Korea, Yeoksamdong
Co-Investments: 1
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 1
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 1
AA
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 1

What are some of recent deals done by Daphne Teo?

Synlogic

Cambridge, Massachusetts, United States

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.

BiotechnologyHealth CareTherapeutics
Series CMay 16, 2017
Amount Raised: $42,000,000